BridgeBio reports real‑world evidence that acoramidis cuts event risk versus tafamidis in ATTR‑CM
BridgeBio Pharma presented an independent, propensity‑score‑matched analysis of 2,684 U.S. patients with transthyretin amyloid cardiomyopathy (ATTR‑CM) using the Epic COSMOS electronic health record database. The study found that patients newly treated with acoramidis experienced an 18% lower risk of a composite of death, all‑cause hospitalization, new‑onset atrial fibrillation or diuretic intensification compared with those on tafamidis. Hospitalization risks were also reduced by roughly a quarter, with 27% lower cardiovascular and heart‑failure admissions and 25% lower all‑cause admissions. The data were presented at the Heart Failure Society of America 2026 meeting.
Why it matters
The company says the findings reinforce acoramidis’ differentiation from the current standard of care, which could support market share gains and justify a higher valuation; the stock closed up 0.48% after the release.
Key facts
- 1The analysis included 2,684 individuals with ATTR‑CM from the Epic COSMOS database. stocktitan.net
- 2After propensity‑score matching, 910 patients were in the acoramidis group and 1,774 in the tafamidis group. stocktitan.net
- 3Acoramidis was associated with an 18% lower risk of the composite endpoint of death, all‑cause hospitalization, new‑onset atrial fibrillation or diuretic intensification (HR 0.82, p<0.01). finance.yahoo.com
- 4Hospitalization risk was 27% lower for cardiovascular admissions (HR 0.73, p<0.001) and 27% lower for heart‑failure admissions (HR 0.73, p<0.001). stocktitan.net
- 5All‑cause hospitalization risk was 25% lower with acoramidis (HR 0.75, p<0.001). stocktitan.net
- 6Diuretic intensification was 17% lower in the acoramidis group (HR 0.83, p<0.01). finance.yahoo.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.